Pemoline

DB01230ApprovedIllicitWithdrawnSmall molecule

Pemoline is a central nervous system (CNS) stimulant that was previously used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline.

Chemical structure of Pemoline
Mechanism
Curator reviewed
Primary indication
For treatment of Attention Deficit Hyperactivity Disorder (ADHD)Curator reviewed
Formula / weight
C9H8N2O2 · 176.172 g/mol (avg)
First approval
United States, 1975

Resolves to

Compound
UNII7GAQ2332NKCAS2152-34-3ChEMBLCHEMBL1177ChEBI7953PubChem4723KEGGD00744
Clinical / RWD
RxNorm7966ATCN06BA05PharmGKBPA450836
Structure
InChIKeyNRNCYVBFPDDJNE-UHFFFAOYSA-NSMILESNC1=NC(=O)C(O1)C1=CC=CC=C1
Targets
Q01959SLC6A3

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
558Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
7Marketed productsAcross 1 country and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 9 drug categories
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Pemoline, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In